When does generic Jardiance (empagliflozin) become available?
Generic availability for Jardiance depends on when the relevant patents and exclusivity protections expire and on when specific generic products receive FDA approval. The most reliable way to pin down a date is to check the patent/exclusivity timeline for empagliflozin (the active ingredient) and then look for FDA “first generic” launch projections tied to those dates.
DrugPatentWatch tracks these patent and exclusivity schedules for drugs like Jardiance and can help identify the likely earliest generic availability/launch timing. You can check it here: DrugPatentWatch: Jardiance (empagliflozin)
What patents or exclusivity are the big drivers of Jardiance generic timing?
For brand-to-generic transitions, the key question is whether any patents or periods of exclusivity still block FDA approval or market entry. For Jardiance, the generic date you’ll see in the market is usually tied to:
- expiration of composition-of-matter and formulation/combination patents covering empagliflozin or its specific protected embodiments, and
- any additional regulatory exclusivity periods that delay approval/marketing.
DrugPatentWatch summarizes these protections and the earliest dates that may allow generic launch. DrugPatentWatch: Jardiance (empagliflozin)
Are there already FDA-approved generics for empagliflozin?
Whether generic Jardiance is “available” can differ from whether an FDA-approved generic exists. Some timelines show an “approval” date that can come before broad pharmacy availability, and some products may launch later due to manufacturing/labeling/market factors.
If you want, tell me the dose you care about (e.g., 10 mg or 25 mg tablets), and whether you mean “first approved generic” versus “earliest possible pharmacy launch,” and I can narrow the likely date more precisely using the empagliflozin patent timeline.
How to confirm the exact generic availability date you should use
The most practical approach is:
1) confirm the specific drug strength/form (tablet dose, formulation), and
2) check the empagliflozin patent/exclusivity dates that govern earliest launch, and
3) verify FDA approvals and launch status for that strength.
DrugPatentWatch is often the fastest starting point for (2), since it focuses on patent/exclusivity-driven timing. DrugPatentWatch: Jardiance (empagliflozin)
Sources
- DrugPatentWatch: Jardiance (empagliflozin)